A 45-year-old man is admitted to the hospital for sepsis secondary to osteomyelitis. He has diabetes mellitus, hypertension, and stage 3 chronic kidney disease (CKD), with a glomerular filtration rate of 46 mL/min/1.73m². He is treated with intravenous (IV) antibiotics and improves clinically. He will need 6 weeks of IV antibiotics after discharge. Should a peripherally inserted central catheter (PICC) be placed for IV access?

The decision to place a PICC must be individualized for the patient. Current guidelines do not provide explicit contraindications for creating permanent vascular access, but the general consensus is that poor candidates include those with advanced dementia, left ventricular ejection fraction less than 20%, poor vasculature on imaging, or terminal illness (life expectancy < 6–12 months).1 In addition, national guidelines and the American Board of Internal Medicine’s Choosing Wisely initiative recommend against PICC placement in patients expected to need permanent dialysis access in the future (CKD stages 3–5).2

■ PICC PROS: CONVENIENCE, LOW COST
PICCs have become increasingly popular in recent years due to their ease of placement, convenience for patients, and cost-effective maintenance. Up to 56% of PICCs are placed to administer IV antibiotics.3

■ PICC CONS: BLOOD VESSEL RISKS
PICCs are highly associated with phlebitis, thromboembolism, central vein thrombosis, and stenosis of the involved vessels, which may obliterate the involved veins and prevent their use for future creation of a permanent dialysis access.4 Clinically diagnosed thrombosis has been reported to occur in 1% to 4% of patients with a PICC. However, in a 2000 study using venography to evaluate patency of the vessels, Allen et al5 reported a much higher incidence, with thrombosis evident in 23.3% of patients after PICC insertion.

Higher rates of thrombosis are associated with larger catheter sizes, the use of cephalic veins (due to smaller size compared with basilic veins), greater number of lumens, placement of multiple catheters, and patient factors including malignancy or history of venous thromboembolism.5,6 Central venous stenosis may also occur, although it is not as common as thrombosis.7

PICC insertion is also a strong independent risk factor for failure of an arteriovenous fistula, the preferred method of vascular access for hemodialysis.7 McGill et al,8 in a 2016 observational study, found that PICC insertion before or after initiation of hemodialysis was associated with failure to transition to a form of permanent access, with only 24.7% of patients transitioning to a working arteriovenous fistula, and 11.5% transitioning to a functioning arteriovenous graft. This is very important because the transition from central venous access to an arteriovenous fistula or graft is associated with better survival and fewer hospitalizations, due to lower risk of serious infections such as endocarditis and bacteremia.8

In patients such as our 45-year-old man, an end-stage kidney disease (ESKD) life plan should be created with input from a nephrologist to determine early access needs and to avoid unnecessary procedures and complications, while also considering life expectancy.

Q: Can I place a peripherally inserted central catheter in my patient with chronic kidney disease?

A: The decision to place a PICC must be individualized for the patient. Current guidelines do not provide explicit contraindications for creating permanent vascular access, but the general consensus is that poor candidates include those with advanced dementia, left ventricular ejection fraction less than 20%, poor vasculature on imaging, or terminal illness (life expectancy < 6–12 months).1 In addition, national guidelines and the American Board of Internal Medicine’s Choosing Wisely initiative recommend against PICC placement in patients expected to need permanent dialysis access in the future (CKD stages 3–5).2

■ PICC PROS: CONVENIENCE, LOW COST
PICCs have become increasingly popular in recent years due to their ease of placement, convenience for patients, and cost-effective maintenance. Up to 56% of PICCs are placed to administer IV antibiotics.3

■ PICC CONS: BLOOD VESSEL RISKS
PICCs are highly associated with phlebitis, thromboembolism, central vein thrombosis, and stenosis of the involved vessels, which may obliterate the involved veins and prevent their use for future creation of a permanent dialysis access.4 Clinically diagnosed thrombosis has been reported to occur in 1% to 4% of patients with a PICC. However, in a 2000 study using venography to evaluate patency of the vessels, Allen et al5 reported a much higher incidence, with thrombosis evident in 23.3% of patients after PICC insertion.

Higher rates of thrombosis are associated with larger catheter sizes, the use of cephalic veins (due to smaller size compared with basilic veins), greater number of lumens, placement of multiple catheters, and patient factors including malignancy or history of venous thromboembolism.5,6 Central venous stenosis may also occur, although it is not as common as thrombosis.7

PICC insertion is also a strong independent risk factor for failure of an arteriovenous fistula, the preferred method of vascular access for hemodialysis.7 McGill et al,8 in a 2016 observational study, found that PICC insertion before or after initiation of hemodialysis was associated with failure to transition to a form of permanent access, with only 24.7% of patients transitioning to a working arteriovenous fistula, and 11.5% transitioning to a functioning arteriovenous graft. This is very important because the transition from central venous access to an arteriovenous fistula or graft is associated with better survival and fewer hospitalizations, due to lower risk of serious infections such as endocarditis and bacteremia.8

In patients such as our 45-year-old man, an end-stage kidney disease (ESKD) life plan should be created with input from a nephrologist to determine early access needs and to avoid unnecessary procedures and complications, while also considering life expectancy.

doi:10.3949/ccjm.88a.20173
and kidney replacement alternatives.2

■ CASE CONTINUED

The team decides to place a PICC through the right basilic vein (Figure 1), and the infection resolves with 6 weeks of IV antibiotics. However, 4 months later, he is readmitted for acute kidney injury and recurrence of osteomyelitis with a paravertebral abscess. The abscess is surgically drained, and the infectious disease consult recommends 8 weeks of IV antibiotics. After a thorough discussion with the nephrology team and the patient, the decision is made against placing a PICC.

■ PICC ALTERNATIVES

Unfortunately, all methods of IV access can produce venous damage, either by direct trauma at the puncture site or by device contact along the walls of the vein.9 It has been hypothesized that the more area within a vessel that a foreign object occupies, the greater the possibility of thrombosis due to increased stasis and direct-contact damage.3 However, midline catheters, which are also inserted into peripheral veins but occupy a smaller ending near the axilla, have also been associated with symptomatic venous thrombosis.4 Catheter location plays an important role, with guidelines suggesting avoiding cephalic, basilic, brachial, and subclavian veins.2,4

A proposed alternative to a PICC is a small-bore, 4-French or 6-French tunneled internal jugular catheter (Figure 2). It tends to last longer and is associated with fewer complications, decreasing the risk of central venous stenosis.10,11 A 2017 retrospective study by Bhutani et al10 found lower rates of deep vein thrombosis in tunneled small-bore central venous catheters than with PICCs, which may be explained by the shorter length of the catheter and better catheter-to-vein size ratio. However, whether they produce less damage to the peripheral vessels or cause central vein stenosis has not been fully studied.1

It has also been suggested that placement of internal jugular catheters by a skilled proceduralist with ultrasonographic and fluoroscopic guidance may result in less venous trauma, reducing the risk of vessel stenosis compared with nonguided methods.11
But even after an arteriovenous fistula has been successfully created, patients with ESKD requiring hemodialysis must continue vessel-preservation strategies as part of their ESKD management plan. If IV antibiotics are needed, it may be possible to select an agent that can be administered 3 times a week on dialysis days, using the functioning hemodialysis access. This will avoid the need for a different catheter, decreasing the risk of central venous stenosis and allowing for the creation of other arteriovenous fistulas if the current one fails.

**Lifelong vessel-preservation strategies**

Patients who may progress to ESKD and may require hemodialysis access in the future should be identified early so that they can be provided with timely education regarding vessel preservation. This includes patients with stage 3 to stage 5 CKD, patients already on kidney replacement therapy such as hemodialysis or peritoneal dialysis, and patients who have a functional transplanted kidney. Such patients should be encouraged to advocate to preserve their vessels and work with the treatment team in balancing the risks and benefits of every intervention, including blood draws and use of IV and arterial devices. Medical alert bracelets and signs at the bedside of hospitalized patients with CKD indicating the need to restrict needle use is essential in educating and alerting the medical community.

It has also been proposed that a nephrology consult be requested before placing a PICC in patients with advanced CKD (stages 3–5). Patients and health professionals are encouraged to visit the website [www.saveyourvein.org](http://www.saveyourvein.org) to further educate themselves on the importance of vein preservation.

**DISCLOSURES**

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

---

**REFERENCES**


**Address:** Nora Hilda Hernandez Garcilazo, MD, Department of Internal Medicine, Michigan State University, Medical Arts Building, 1322 E. Michigan Ave. Suite 300, Lansing, MI 48912; herna644@msu.edu